Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Looks like it bottomed out. Get'em while they are cheap!!

<< Previous

Bullboard Posts

Next >>

Comment by JimmyJon Feb 18, 2021 8:08pm

154 Views

Post# 32605752

RE:Looks like it bottomed out. Get'em while they are cheap!!

I don't know about $7 in a week but I do like I your enthusiasm. Im anticipating more of a slow bleed to the mid-low 5's unless we get some quick news (unlikely). I also see this as a healthy (planned) market correction, I mean a 40% gain already this year (and now stabilized) is not bad at all.

Check BLDP as a recent example of slow bleed after a bought deal this year. They went from$29-$52 over a few weeks in January, and then lost the wind in their sales on with the TD Securities bought deal at $46cdn/share. It's been a slow bleed ever since and doesn't appear to have found bottom yet.

<< Previous

Bullboard Posts

Next >>

Canadian artificial intelligence ETFs